inositol 1,4,5-trisphosphate | 1219383-17-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: inositol 1,4,5-trisphosphate
• 英文别名: (2,3,5-Trihydroxy-4,6-diphosphonooxycyclohexyl) dihydrogen phosphate
• CAS: 1219383-17-1
• 化学式: C₆H₁₅O₁₅P₃
• 分子量: 420.097
• InChiKey: MMWCIQZXVOZEGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  261
• 氢给体数：
  9
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  dibenzyl [2,4-bis[bis(phenylmethoxy)phosphoryloxy]-6-(phenoxymethyl)-3,5-bis(phenylmethoxy)cyclohexyl] phosphate 以64%的产率得到
  参考文献：
  名称：

  VACCA, JOSEPH P.;SOIMS, S. JANE DE;HUFF, JOEL R.;BILLINGTON, DAVID C.;BAK+, TETRAHEDRON, 45,(1989) N7, C. 5679-5702

  摘要：

  DOI：

文献信息

• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：Whitten Jeffrey P.

  公开号：US20110263612A1

  公开（公告）日：2011-10-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或症状。
• [EN] ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION<br/>[FR] INHIBITEURS CHROMÉNONE ALLOSTÉRIQUES DE LA PHOSPHOINOSITIDE 3-KINASE (PI3K) POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA MODULATION DE PI3K
  申请人：PETRA PHARMA CORP

  公开号：WO2021202964A1

  公开（公告）日：2021-10-07

  The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.

  该披露涉及到式(I)的化合物，作为磷脂酰肌醇3-激酶（PI3K）的变构色酮抑制剂，在与PI3K调节相关的疾病或紊乱的治疗中有用，式(I)，或其前药、溶剂化合物、对映体、立体异构体、互变异构体或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、W、X、Y、s和环A如本文所述。
• [EN] OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE<br/>[FR] RÉGIMES POSOLOGIQUES D'ANTAGONISTES DE L'OCYTOCINE POUR FAVORISER L'IMPLANTATION D'EMBRYONS ET PRÉVENIR LES FAUSSES COUCHES
  申请人：OBSEVA SA

  公开号：WO2021043726A1

  公开（公告）日：2021-03-11

  The disclosure provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives of formula (I), among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and methods of the disclosure can be used to dose subjects with oxytocin antagonists, including (3Z,5S)-5-(hydroxymethyl)-l-[(2'- methyl-l,l'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, among others, so as to improve endometrial receptivity and reduce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intra cytoplasmic sperm injection (ICSI) embryo transfer procedures. (Formula I)

  该公开提供了有关使用催产素拮抗剂的组合物和方法，例如式(I)的取代吡咯烷-3-酮肟衍生物，以及其他化合物，用于治疗接受胚胎移植治疗的受试者。该公开的组合物和方法可用于给予催产素拮抗剂剂量，包括(3Z,5S)-5-(羟甲基)-l-[(2'- 甲基-1,1'-联苯基-4-基)羰基]吡咯烷-3-酮O-甲氧肟等，以改善子宫内膜的接受性，并减少例如体外受精（IVF）和单精子细胞内注射（ICSI）胚胎移植程序后胚胎着床失败和流产的可能性。(式I)
• Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
  申请人：Marks R. Andrew

  公开号：US20050215540A1

  公开（公告）日：2005-09-29

  The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

  本发明提供了限制或预防受试者中RyR2结合FKBP12.6水平下降的方法。本发明进一步提供了治疗和预防受试者中心房和心室心律失常、心力衰竭以及运动诱发的突发性心脏死亡的方法。此外，本发明提供了在限制或预防受试者中RyR2结合FKBP12.6水平下降的方法中使用JTV-519的用途，该受试者患有或有可能患上心房颤动。还提供了1,4-苯并噻唑啉衍生物在治疗和预防受试者中心房和心室心律失常以及心力衰竭，以及预防运动诱发的突发性心脏死亡的方法中的用途。本发明还提供了用于识别用于治疗和预防心房颤动和心力衰竭的药剂的方法，以及通过这些方法识别的药剂。
• INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：INOUE Teruhiko

  公开号：US20110306599A1

  公开（公告）日：2011-12-15

  Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as described in the specification.

  提供了一种用于治疗或预防炎症性疾病、过敏性疾病、自身免疫性疾病、移植排斥等的药剂。该药剂包括以下式[I]所代表的化合物或其药用可接受的盐，或其溶剂化合物：其中每个符号如规范中所述。